REG - PureTech Health PLC - PureTech Appoints Robert Lyne as CEO

Puretech HealthAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251218:nRSR0355Ma&default-theme=true

RNS Number : 0355M  PureTech Health PLC  18 December 2025

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF
THE UK VERSION OF THE MARKET ABUSE REGULATION (EU 596/2014) AS IT FORMS PART
OF UK LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED

 

18 December 2025

PureTech Health plc

 

PureTech Appoints Robert Lyne as Chief Executive Officer

 

PureTech Health plc (https://puretechhealth.com/) (Nasdaq: PRTC, LSE: PRTC)
("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company
dedicated to giving life to science and transforming innovation into value,
today announces that the Board of Directors has appointed Robert Lyne as Chief
Executive Officer (CEO), and as a member of the Board of Directors, effective
immediately.

 

Robert Lyne commented: "I'm honored to lead PureTech as CEO at such an
important moment in its evolution. Over the past two years, I've seen
first-hand the strength of our programs, the talent of our team, and the power
of our differentiated model. I'm keen to build on this foundation, working
closely with the Board to drive the next phase of execution as we advance
transformative therapies for patients and deliver long-term value for our
shareholders.

 

"Our immediate focus is on securing the funding needed to advance our newest
Founded Entity, Celea Therapeutics, following the successful End-of-Phase 2
meeting with the U.S. Food and Drug Administration. This process is
progressing, and we expect to close within the first half of 2026, after which
PureTech's operational run rate will reduce significantly. In parallel, we are
also actively pursuing financing in 2026 for Gallop Oncology, as the strong
initial topline data continue to mature, and the program advances to the next
stage of development.

 

"Going forward, we intend to operate with a streamlined structure and
significantly reduced overhead. This will be combined with a disciplined
investment posture, pursuing focused innovation initiatives that can be
advanced to key inflection points with relatively modest spend to improve our
return on capital. Once Celea is fully financed, we expect to evaluate the
most effective means of delivering value to shareholders, including potential
capital returns, as part of an integrated strategy that continues targeted and
impactful innovation. In the meantime, our priority is preserving capital,
maintaining flexibility, and positioning PureTech for value creation."

 

Sharon Barber-Lui, Interim Chair of PureTech's Board of Directors, said: "We
are pleased to appoint Rob as PureTech's CEO. As Interim CEO, Rob has
demonstrated strong leadership, strategic clarity, and a deep understanding of
the business and key stakeholders. Rob's appointment positions the Company to
execute against a clear plan to sharpen strategic and operational focus and
optimize shareholder returns. The Board supports Rob's disciplined approach to
maintaining a lean operating model whilst concentrating on capital-efficient
innovation to maximize shareholder value. The Board is confident that Rob is
the right person to lead PureTech forward."

 

Mr. Lyne has served as Interim CEO since July 2025 and joined PureTech in
January 2024 as Chief Portfolio Officer. During his time as Interim CEO, Mr.
Lyne has provided strong leadership for the business, overseeing progress
across PureTech's programs and advancing strategic and operational priorities.
He is an experienced leader of UK-listed life science innovation and venture
capital companies, having previously served as CEO of Arix Bioscience plc. Mr.
Lyne brings more than a decade of experience in senior leadership roles at
London-listed life science companies, with a strong track record in governance
and executive team leadership. He has been involved in over 80 venture capital
financings across Europe and North America as well as multiple portfolio exits
and initial public offerings.

 

Mr. Lyne was previously a director of Arix Bioscience plc within the past five
years. There are no other details to be disclosed in respect of Mr. Lyne's
appointment pursuant to LR 9.6.13R.

 

About PureTech Health

PureTech Health is a hub-and-spoke biotherapeutics company dedicated to giving
life to science and transforming innovation into value. We do this through a
proven, capital-efficient R&D model focused on opportunities with
validated pharmacology and untapped potential to address significant patient
needs. This strategy has produced dozens of therapeutic candidates, including
three that have received U.S. FDA approval. By identifying, shaping, and
de-risking these high-conviction assets, and scaling them through dedicated
structures backed by external capital, we accelerate their path to patients
while creating sustainable value for shareholders.

 

For more information, visit www.puretechhealth.com or connect with us on X
(formerly Twitter) @puretechh.

 

Cautionary Note Regarding Forward-Looking Statements

This press release contains statements that are or may be forward-looking
statements within the meaning of the Private Securities Litigation Reform Act
of 1995. All statements contained in this press release that do not relate to
matters of historical fact should be considered forward-looking statements,
including without limitation statements that relate to our expectations around
our therapeutic candidates and approach towards addressing major diseases, our
plans to advance our programs and deliver on our milestones, our future plans,
prospects, developments, and strategies. The forward-looking statements are
based on current expectations and are subject to known and unknown risks,
uncertainties and other important factors that could cause actual results,
performance and achievements to differ materially from current expectations,
including, but not limited to, those risks, uncertainties and other important
factors described under the caption "Risk Factors" in our Annual Report on
Form 20-F for the year ended December 31, 2024 filed with the SEC and in
our other regulatory filings. These forward-looking statements are based on
assumptions regarding the present and future business strategies of the
Company and the environment in which it will operate in the future. Each
forward-looking statement speaks only as at the date of this press release.
Except as required by law and regulatory requirements, we disclaim any
obligation to update or revise these forward-looking statements, whether as a
result of new information, future events or otherwise.

 

Contact:

PureTech

Investor Relations

IR@puretechhealth.com (mailto:IR@puretechhealth.com)

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAFVLBFELLXFBQ



            Copyright 2019 Regulatory News Service, all rights reserved